Massachusetts-based Quanterix Corporation announced that it has brought in $46 million in a Series D round of financing. The company is focused on ultrasensitive single molecule testing capabilities.
The reported additional capital, according to a company statement, will be used to develop desk-top instruments, expand the assay menu for protein and nucleic acid biomarkers, bolster the global channel to market and enable new medical studies to be performed with Quanterix’ current technology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Quanterix’ Simoa platform has already been profiled in 57 peer reviewed publications. The company’s therapeutic areas of focus include neurology, oncology, cardiology, inflammation and infectious disease. Utilizing liquid biopsies and other forms of early detection are integral in Quanterix’ technology designed to help detect disease before symptoms are even present.
ARCH Overage Fund, Cormorant Asset Management and Trinitas Capital led the financing, and existing investors, ARCH Venture Partners, Bain Capital Ventures, Tufts University and Dr. David Walt. Hercules Capital, Inc. also participated.
Photo: Screenshot via Quanterix
